On September 14, 2020 Agendia, Inc. a world leader in precision oncology for breast cancer reported that new clinical data from its ongoing research in breast cancer is to be presented at the upcoming European Society for Medical Oncology (ESMO) (Free ESMO Whitepaper) Virtual Congress 2020, September 19-21 (Press release, Agendia, SEP 14, 2020, View Source [SID1234565123]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The first presentation will feature data on the use of MammaPrint to determine the need for endocrine therapy in postmenopausal patients. The findings of this study build on data from the Stockholm Tamoxifen Trial, previously published by Esserman, et al in JAMA Oncology. The second presentation will illustrate the fact that the 10 Hallmarks of Cancer, as described by Hanahan and Weinberg, are represented in the genomic signatures of MammaPrint and BluePrint.
"We are very pleased with the data that has been selected for presentation at this year’s virtual ESMO (Free ESMO Whitepaper) congress," said William Audeh, MD, Chief Medical Officer of Agendia, Inc. "We are excited to share these updates with world-renowned oncologists, researchers and the broader oncology community, to further highlight the essential value of MammaPrint and BluePrint for clarifying the complexity of breast cancer, and guiding treatment decisions that are the right fit for patients with early stage breast cancer."
The following posters will be available on the ESMO (Free ESMO Whitepaper) Website in the On-Demand E-Poster Display section beginning Thursday, September 17th at 9:00 AM CEST.
Presentation 171P: Avoid systemic overtreatment of postmenopausal breast cancer patients with ultralow MammaPrint result
Presentation 220P: Annotating MammaPrint and BluePrint gene profile to the Hallmarks of cancer and understanding the biology of MammaPrint extreme risk groups
These data underscore Agendia’s mission to further research and provide new tools that support early intervention and treatment planning for patients with breast cancer. For further information, please visit View Source
Please follow us on our Twitter, Facebook and LinkedIn pages for unique content we will be sharing throughout ESMO (Free ESMO Whitepaper) 2020.